Flavia Ferrantelli

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Neutralizing antibodies against HIV -- back in the major leagues?
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Immunol 14:495-502. 2002
  2. ncbi request reprint Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Virology 358:69-78. 2007
  3. ncbi request reprint Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 189:2167-73. 2004
  4. ncbi request reprint Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 189:71-4. 2004
  5. ncbi request reprint Antibody protection: passive immunization of neonates against oral AIDS virus challenge
    Ruth M Ruprecht
    Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Vaccine 21:3370-3. 2003
  6. ncbi request reprint Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B
    Moiz Kitabwalla
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 19:125-31. 2003
  7. ncbi request reprint Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    AIDS 17:301-9. 2003
  8. pmc Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates
    Agnes Laurence Chenine
    Department of Cancer Immunology, Dana Farber Cancer Institute, 44 Binney Street, JFB809, Boston, MA 02115 6084, USA
    J Virol 79:1333-6. 2005
  9. ncbi request reprint Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV
    Flavia Ferrantelli
    Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street JFB809, Boston, MA 02115, USA
    Vaccine 20:A61-5. 2002
  10. ncbi request reprint DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Vaccine 24:2324-32. 2006

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Neutralizing antibodies against HIV -- back in the major leagues?
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Immunol 14:495-502. 2002
    ..Epitopes recognized by the protective monoclonal antibodies are important determinants for protection and provide a rational basis for AIDS vaccine development...
  2. ncbi request reprint Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Virology 358:69-78. 2007
    ..Taken together with our results from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window between virus exposure and start of immunotherapy...
  3. ncbi request reprint Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 189:2167-73. 2004
    ..These data are important for designing clinical trials in human neonates and have general implications for AIDS vaccine development, as the epitopes recognized by the 3 nMAbs are conserved among diverse primary isolates...
  4. ncbi request reprint Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 189:71-4. 2004
    ..The in vitro cross-group neutralization shown here underscores the broad potential of these nMAbs against divergent virus variants and the relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines...
  5. ncbi request reprint Antibody protection: passive immunization of neonates against oral AIDS virus challenge
    Ruth M Ruprecht
    Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Vaccine 21:3370-3. 2003
    ....
  6. ncbi request reprint Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B
    Moiz Kitabwalla
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 19:125-31. 2003
    ..We and others also showed neutralization of primary HIV clade B strains. Together, our data show that the quadruple combination of mAbs effectively neutralized primary HIV clade A, B, C, and D isolates...
  7. ncbi request reprint Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    AIDS 17:301-9. 2003
    ..The majority of infants infected through maternal transmission acquire the virus during birth or postpartum through breastfeeding: mucosal exposure is considered to be a major route of infection...
  8. pmc Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates
    Agnes Laurence Chenine
    Department of Cancer Immunology, Dana Farber Cancer Institute, 44 Binney Street, JFB809, Boston, MA 02115 6084, USA
    J Virol 79:1333-6. 2005
    ..Thus, route of inoculation and age are important determinants of SHIV89.6P infectivity in rhesus macaques...
  9. ncbi request reprint Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV
    Flavia Ferrantelli
    Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street JFB809, Boston, MA 02115, USA
    Vaccine 20:A61-5. 2002
    ..We suggest that the epitopes identified by passive immunization represent excellent targets for the rational design of nAb response-based AIDS vaccines...
  10. ncbi request reprint DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Vaccine 24:2324-32. 2006
    ..The results demonstrate the utility of this DNA prime/protein boost approach to generate cellular immunity, as well as neutralizing antibodies, against HIV clade C env antigens...
  11. ncbi request reprint Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines
    Flavia Ferrantelli
    AIDS Division, Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Curr Opin Biotechnol 15:543-56. 2004
    ....
  12. ncbi request reprint Immunoprophylaxis to prevent mother-to-child transmission of HIV-1
    Jeffrey T Safrit
    Elizabeth Glaser Pediatric AIDS Foundation, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Acquir Immune Defic Syndr 35:169-77. 2004
    ..Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years...
  13. ncbi request reprint Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env
    Barbara Ensoli
    AIDS National Center, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Roma, Italy
    Microbes Infect 7:1392-9. 2005
    ....
  14. ncbi request reprint Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience
    Flavia Ferrantelli
    National AIDS Center, Istituto Superiore di Sanita, V le Regina Elena 299, 00161, Rome, Italy
    Springer Semin Immunopathol 28:289-301. 2006
    ..The building of the AVIP consortium and its scientific strategy will be reviewed in this paper as an example of the establishment of a consortium regulated by a specific intellectual property agreement...
  15. ncbi request reprint Problems and emerging approaches in HIV/AIDS vaccine development
    Fausto Titti
    Istituto Superiore di Sanita, National AIDS Center, V le Regina Elena 299, Rome 00161, Italy
    Expert Opin Emerg Drugs 12:23-48. 2007
    ..These non-structural proteins alone or in combination with modified structural HIV-1 Env proteins represent a novel strategy for both preventative and therapeutic HIV/AIDS vaccine development...